A phase 1 trial to demonstrate intra-bladder route of administration (PK data) in cUTI patients with resistant E. Coli infections in the bladder
Latest Information Update: 21 May 2024
At a glance
- Drugs PP 1493 (Primary) ; PP 1815 (Primary)
- Indications Escherichia coli infections; Urinary tract infections
- Focus Pharmacokinetics
- Sponsors PHAXIAM Therapeutics
- 15 May 2024 According to a PHAXIAM media release, company has received the validation from the ANSM (French Regulatory agency) to initiate this sponsored clinical trial in France, subject to available financing.
- 29 Sep 2023 New trial record
- 21 Sep 2023 According to a PHAXIAM media release, CTA submission in France planned before end of year 2023.